Immunitybio is trading 4.11% higher now at $8.87 on September 29, 2026, with no clear company-specific catalyst identified. - Recent coverage has focused on earlier developments, including international expansion and second-quarter revenue growth; neither is established as the cause of this move. - Major indices are slightly lower, and available sources provide no dependable current volume or activity-level detail.